Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: selective estrogen receptor-beta agonists - Karo Pharma

Drug Profile

Research programme: selective estrogen receptor-beta agonists - Karo Pharma

Alternative Names: KB093823; KB095285; KB095508; KB099520; KB285; KB9520; KB9580

Latest Information Update: 28 Apr 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Karo Bio
  • Class
  • Mechanism of Action Selective estrogen receptor beta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Multiple sclerosis

Highest Development Phases

  • No development reported Cancer; Genitourinary disorders; Mesothelioma; Multiple sclerosis
  • Discontinued Major depressive disorder

Most Recent Events

  • 28 Apr 2018 No recent reports of development identified for preclinical development in Mesothelioma in Sweden (PO)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Sweden (PO)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Genitourinary-disorders in Sweden (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top